JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2009, 58(4):150-154

Cardioprotective effect of 2',3,4'--trihydroxychalcone in preclinical experiment

L. Bartošíková1,*, J. Nečas1, T. Bartošík2, M. Pavlík2, V. Perlík1
1 Palacký University in Olomouc, Faculty of Medicine, Department of Physiology, Czech Republic
2 St Anne's Faculty Hospital Brno, Clinic of Anesthesiology and Resuscitation, Czech Republic

2',3,4'-trihydroxychalcone is a newly synthesized substance with antioxidant properties. The aim of this pilot study was to monitor its effect during heart perfusion in the laboratory rat.
The study included two groups of animals of the same number (n = 10). The 1st group was pretreated with chalcone in a dose of 10 mg/kg p.o. during 15 days. The 2nd group was a placebo one. After i.p. administration of a heparin injection of 500 IU dose, the hearts were excised and perfused (a modified Langendorf's method). Working schedule: stabilization/ischaemia/reperfusion proceed at intervals of 20/30/60 min. Monitored parameters in the isolated heart: left ventricle pressure (LVP), end-diastolic pressure (LVEDP), contractility (+dP/dtmax). The treated hearts showed improved postischemic recovery, reaching LVP values of 101 ± 4% at the end of reperfusion, the placebo ones only 42 ± 6%. In the placebo hearts LVEDP increased from 10.0 ± 0.5 mm Hg to 32 ±5 mm Hg after, in treated animals only about 10.5 ± 2 mm Hg. The treated hearts improved +dP/dtmax recovery during reperfusion to 92 ± 7 %. These values were significantly greater than those obtained from the placebo hearts. We conclude that the administration of 2',3,4'--trihydroxychalcone in laboratory rats has a cardioprotective potential against ischemia-reperfusion induced injury.

Keywords: ischemia, reperfusion of heart; 2',3,4'-trihydroxychalcone; laboratory rat

Received: June 10, 2024; Accepted: July 8, 2009; Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartošíková L, Nečas J, Bartošík T, Pavlík M, Perlík V. Cardioprotective effect of 2',3,4'--trihydroxychalcone in preclinical experiment. Čes. slov. farm. 2009;58(4):150-154.
Download citation

References

  1. Margit, P., Elizabeth, R., Gabor, M.: Pharmacol. Res., 1996; 33, 327-336.
  2. Lin, W. T., Yang, S.C., Chen, K. T., Huang, C. C., Lee, N. Y.: Acta Pharmacol. Sin., 2005; 26, 992-999. Go to original source... Go to PubMed...
  3. Wei, A. N., Jing, Y., Ying, A. O.: Acta Pharmacol. Sin., 2006; 10, 1431-1437.
  4. Kaminski, K. A., Bonda, T. A., Korecki, J., Musial, W. J.: Int. J. Cardiol., 2002; 86, 41-59. Go to original source... Go to PubMed...
  5. Bak, I., Lekli, I., Juhasz, B., Nagy, N., Varga, E., Varadi, J., Gesztelyi, R., Szabo, G., Szendrei, L., Bacskay, I., Vecsernyes, M., Antal, M., Fesus, L., Boucher, F., Leiris, J., Tosaki, A.: Am. J. Physiol. Heart Circ. Physiol., 2006; 291, H1329-H1336. Go to original source... Go to PubMed...
  6. Hasselbaink, D. M., Glatz, J. F., Luiken, J. J., Roemen, T. H., Van der Vusse, G. J.: Biochem. J., 2003; 371, 753-760. Go to original source... Go to PubMed...
  7. Tejero-Taldo, M. I., Gursoy, E., Zhao, T. C., Kukreja, R. C.: J. Mol. Cell Cardiol., 2002; 34, 185-195. Go to original source... Go to PubMed...
  8. Splawski, I., Timothy, K. W., Decher, N., Kumar, P., Sachse, F. B., Beggs, A. H., Sanguinetti, M. C., Keating, M. T.: Proc. Natl. Acad. Sci. USA, 2005; 102, 8089-8096. Go to original source... Go to PubMed...
  9. Baker, K. E., Curtis, M. J.: Br. J. Pharmacol, 2004; 142, 352-366. Go to original source... Go to PubMed...
  10. Merkus, D., Houweling, B., van den Meiracker, A. H., Boomsma, F., Duncker, D. J.: Am. J. Physiol. Heart Circ. Physiol, 2005; 288, H871-H880. Go to original source... Go to PubMed...
  11. Fitzpatrick, C. M., Shi, Y., Hutchins, W. C., Su, J., Gross, G. J., Ostadal, B., Tweddell, J. S., Baker, J. E.: Am. J. Physiol. Heart Circ. Physiol., 2005; 288, H62-H68. Go to original source... Go to PubMed...
  12. Bak, I., Szendrei, L., Turoczi, T., Papp, G., Joo, F., Das, D. K., de Leris, J., Der, P., Juhasz, B., Varga, E., Bacskay, I., Kovacs, P., Tosaki, A.: FASEB J., 2003; 17, 2133-2135.
  13. Stein, A. B., Guo, Y., Tan, W., Wu, W. J., Zhu, X., Li, Q., Luo, C., Dawn, B., Johnson, T. R., Motterlini, R., Bolli, R.: J. Mol. Cell. Cardiol., 2005; 38, 127-134. Go to original source... Go to PubMed...
  14. Das, D. K.: Antioxid. Redox Signal., 2001; 3, 23-37. Go to original source... Go to PubMed...
  15. Gross, E. R., Peart, J. N., Hsu, A. K., Grover, G. J., Gross, G. J.: J. Mol. Cell Cardiol., 2003; 35, 985-992. Go to original source... Go to PubMed...
  16. Gustafsson, A. B., Gotlieb, R. A.: J. Clin. Immunol., 2003; 23, 447-459. Go to original source... Go to PubMed...
  17. Lorimer, S. D., Perry, N. B.: Planta Med., 1994; 60, 386-387. Go to original source... Go to PubMed...
  18. Mahmood, N., Piacente, S., Burke, A., Khan, A., Pizza, C.: Antiviral Chem. Chemother., 1997; 8, 70-74. Go to original source...
  19. Min, B., Ahn, B., Bae, K.: Arch. Pharm., 1996; 19, 543-550. Go to original source...
  20. Williams, C. A., Hoult, J. R. S., Harborne, J. B., Greeham, J., Eagler, J.: Phytochemistry, 1995; 38, 267-270. Go to original source... Go to PubMed...
  21. Bartošíková, L., Nečas, J., Bartošík, T., Pavlík, M.: Czech and Slovak Pharmacy, 2008; 6, 249-253.
  22. Kozlovski, V. I., Vdovichenko, V. P., Chlopicki, S., Malci, S. S., Praliyev, Z. D., Zcilkibayev, O. T.: Pol. J. Pharmacol., 2004; 56, 767-774.
  23. Ikizler, M., Erkasap, N., Dernek, S., Kurual, T., Kaygisiz, Z.: Anadolu Kardiol. Derg., 2007; 7, 404-410.
  24. Zweier, J. L.: J. Biol. Chem., 1988; 263, 1353-1357. Go to original source...
  25. Curin, J., Andriantsitohaina, R.: Pharmacol. Reports, 2005; 57 (Suppl.), 97-107.
  26. Lebeau, J., Neviere, R., Cotelle, N.: Bioorg. Med. Chem. Letters, 2001; 11, 23-27. Go to original source... Go to PubMed...
  27. Alyane, M., Kebsa, L. B. W., Boussenane, H. N., Rouibah, H., Lahouel, M.: Pak. J. Pharm. Sci., 2008; 21, 201-209.
  28. Yang, B. C., Chen, L. Y., Saldeen, T. G. P., Mehta, J. L.: Br. J. Pharmacol, 1997; 120, 305-311. Go to original source... Go to PubMed...
  29. Yang, B. C., Virmani, R., Nichols, W. W., Mehta, J. L.: Circ. Res., 1993; 72, 1181-1190. Go to original source... Go to PubMed...
  30. Kokita, N., Hara, A., Abiko, Y., Arakawa, J., Hashizume, H., Namiki, A.: Anesth. Analg., 1998; 86, 252-258. Go to original source...
  31. Nečas, J., Bartošíková L., Florian, T., Klusáková, J., Suchý V., Naggar, E. M. B., Janoštíková, E., Bartošík, T., Lišková, M.: Czech and Slovak Pharmacy, 2006; 4, 168-174.
  32. Palacios, I., Johnson, R. A., Newell, J. B., Powell W. J.: Circulation, 1976; 53, 428-436. Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.